Sign in

Shira G-S, PhD

@thehematopoet.bsky.social
108 followers 81 following 10 posts

Scientist studying chromatin organization in myeloid malignancies in the Tothova Lab at the Dana Farber Cancer Institute 👩‍🔬 she/her

PostsRepliesMedia
Shira G-S, PhD @thehematopoet.bsky.social · 01/08/2025
Just getting home after an incredible week at FASEB hematologic malignancies. This is truly the best meeting and I feel so lucky to be able to attend!! The week was too busy to actively post so here’s a little recap thread… #HEMSRC 🩸🔬
151
Shira G-S, PhD @thehematopoet.bsky.social · 15/07/2025
So excited to share a pre-print of my thesis work! Check it out to see how we can leverage an epigenetic resistance mechanism to PI3K inhibitors to target leukemic stem cells!! (Spoiler alert: PRC2 is involved!) Really proud of this work conducted with @gritsmanlab.bsky.social
070
Shira G-S, PhD @thehematopoet.bsky.social · 08/03/2025
Stood up for science in Boston today!! Science saves lives! Keep fighting 🧬🤓💪
062
Shira G-S, PhD @thehematopoet.bsky.social · 24/01/2025
📣Life update📣!! This week I officially started as a postdoc in the Tothova Lab at @danafarber.bsky.social !! So excited to be surrounded by so many amazing scientists doing cutting edge research 👩‍🔬👨‍🔬 Please share your postdoc advice and of course any Boston recs!!
160
Shira G-S, PhD @thehematopoet.bsky.social · 06/12/2024
So sad I am missing #ASH2024 But if you’re there early enough be sure to check out the wonderful @gritsmanlab.bsky.social present exciting updates from my work at the therapy resistance workshop on Friday! 2-5pm in SDCC room 33!
061
Shira G-S, PhD @thehematopoet.bsky.social · 04/12/2024
Overwhelmed by all of the exciting new research on chromatin modifiers in AML? Find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in SCTM! @alexkschurer.bsky.social @gritsmanlab.bsky.social academic.oup.com/stcltm/advan...
academic.oup.com
Targeting chromatin modifying complexes in acute myeloid leukemia
Abstract. Acute myeloid leukemia (AML) is a devastating hematologic malignancy with high rates of relapse, which can, in part, be attributed to the dysregu
1269